We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CDY market cap is 20.47M. The company's latest EPS is AUD -0.0073 and P/E is -1.37.
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 8.27M | 8.53M | 7.33M | 10.98M | 9.93M |
| Operating Income | -5.73M | -4.6M | -3.04M | -3.92M | -1.67M |
| Net Income | -5.91M | -4.91M | -3.39M | -3.65M | -2.67M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 9.79M | 14.89M | 13.29M | 12.93M | 11.11M |
| Total Liabilities | 3.94M | 5.08M | 2.86M | 4.64M | 2.22M |
| Total Equity | 5.86M | 9.81M | 10.43M | 8.29M | 8.9M |
| Year End 30 June 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -5.67M | -4.01M | -4.11M | -2.53M | -1.76M |
| Investing | -66k | N/A | 478k | -968k | -1.51M |
| Financing | 7.28M | 7.98M | 3.5M | 73k | 2.54M |
| Market Cap | 20.47M |
| Price to Earnings Ratio | -1.37 |
| Price to Sales Ratio | 0.37 |
| Price to Cash Ratio | 1.43 |
| Price to Book Ratio | 0.41 |
| Dividend Yield | - |
| Shares Outstanding | 365.62M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (3.45%) |
| Company Name | Cellmid Limited |
| Address |
suite 204 level 2 sydney, new south wales 2000 |
| Website | https://www.anagenics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
